Bruno BUISSON

Since 2020 he has been the president of the Strategic Project Council at EUROBIOMED and works with a team of 18 experts. With 30 years of experience in research projects not only in academic laboratories but also in pharmaceutical and biotechnology companies, he is co-founder of Neuroservice (company created in 2006). Following these studies in biochemistry, he completed a doctorate in electrophysiology/neuropharmacology. He spent 7 years in the laboratory of Daniel Bertrand (University of Geneva) to strengthen his skills and experience in electrophysiological techniques (patch-clamp and multi-electrode array). He made fundamental discoveries about human nicotinic acetylcholine receptors. He was co-winner (with Dr Raphael Holzer), in 1999, of the first Leenaards Foundation Prize for young scientific researchers for an innovative project in neuroscience. As head of pharmacology at TROPHOS (acquired by ROCHE in 2014), he qualified a new drug for the treatment of neuromuscular diseases (olesoxime) to the IND. He is co-author of the global patent Olesoxime, which is the first drug to stop the progression of spinal muscular atrophy (SMA, an orphan disease). After a successful phase 2 with SMA patients, Olesoxime was acquired by ROCHE for €400 million. Bruno is a member of the Society for Neuroscience (SfN, USA), ASPET (USA), the French and European Neuroscience Societies (FENS), the AFSSI board of directors and a member of the Strategic Expert Group of Rising SUD (SOUTH-PACA Region).